CASE REPORT

Acute generalized exanthematous pustulosis x Von Zumbusch’s pustular psoriasis: A diagnostic challenge in a psoriatic patient*

Aline Soares de Sousa¹
Francine Papaiordanou²
Antonio José Tebcherani¹
Osório Alves Corrêa de Castro Lara¹
Gláucia Silva Simioni Marchioro¹

Received on 08.11.2013
Approved by the Advisory Board and accepted for publication on 16.12.2013.

* Study carried out at the Complexo Hospitalar Padre Bento de Guarulhos (CHPBG) – Guarulhos (SP), Brazil.
Financial Support: None.
Conflict of Interest: None.

1 Complexo Hospitalar Padre Bento de Guarulhos (CHPBG) – Guarulhos (SP), Brazil.
2 Instituto de Dermatologia Prof. Rubem David Azulay – Santa Casa da Misericórdia do Rio de Janeiro – Rio de Janeiro (RJ), Brazil.
©2015 by Anais Brasileiros de Dermatologia

DOI: http://dx.doi.org/10.1590/abd1806-4841.20153256

Abstract: Severe cutaneous drug reactions include a wide spectrum of clinical manifestations ranging from mild morbilliform cutaneous rash, to severe forms of hypersensitivity. Special attention is given in this report to the acute generalized exanthematous pustulosis (AGEP), induced in 90% of cases by the use of systemic drugs, especially aminopenicillins and macrolides. The incidence of the disease is low, 1-5 cases per million patients / year. The main differential diagnosis is Von Zumbusch’s Pustular Psoriasis. The prognosis is generally good and the disease self limited, after withdrawal of the triggering drug. In this report the authors describe a case of AGEP, triggered by ceftriaxone in a patient with psoriasis vulgaris.

Keywords: Drug hypersensitivity; Exanthema; Psoriasis

INTRODUCTION

Cutaneous drug reactions encompass a wide spectrum of clinical manifestations that range from mild morbilliform rash to severe forms of hypersensitivity1,2. Special attention is dedicated in this report to acute generalized exanthematous pustulosis (AGEP), which in over 90% of cases is induced by the use of systemic drugs, especially aminopenicillins and macrolides.1,4

The term AGEP was first proposed by Béjot et al; later on Roujeau et al reported a series of 63 cases of the disease, in study published in 1991. 1,3 The first Brazilian case was described by Campbell and Furtado, who described how a patient developed AGEP following the use of ampicillin.

The incidence of the disease is 1 to 5 cases per million patients/year. The mean age of patients is 56 years and both genders are affected, with discreet female predominance. 1 The etiopathogenesis is still not completely understood, although immune mechanisms mediated by T cells and cytokines have the greatest amount of scientific evidence up to the moment. 3,4,5

The main differential diagnosis is Von Zumbusch’s Pustular Psoriasis, formerly regarded as an AGEP variant, but clearly differentiated in more recent investigation (EuroScar study). 4 Some criteria favor the pustular psoriasis diagnosis — history of psoriasis, prolonged fever, pustular rash of longer duration than in AGEP, absence of history of drug exposure and a differentiated histopathological picture. 2,4,6 What makes diagnosis difficult is the fact that patients with psoriasis are more prone to develop AGEP than healthy patients, an affirmation based on statistical data, by means of a mechanism still unknown. 4,5,7

The relationship established between the two nosological entities are the clinical similarities, but there is evidence that they are distinct diseases, as cited above.
In this report the authors describe an AGEP case triggered by ceftriaxone in a patient with psoriasis vulgaris.

**CASE REPORT**

Male patient, 66 years old, from São Paulo, SP, with psoriasis vulgaris antecedent and previous treatment with acitretin. He was referred to the dermatology service due to the sudden onset of exanthema on the trunk and limbs, after use of ceftriaxone for treatment of erysipela. At first he was medicated with IV hydrocortisone, but even with the use of corticosteroids the lesions worsened and progressed with millimeter-sized pustules. The dermatological examination showed erythematous desquamative lesions on the trunk and limbs associated with disseminated pustules, more abundant in flexural areas (Figures 1 and 2). Laboratory tests revealed only leukocytosis, without deviations.

The patient was hospitalized with diagnostic hypotheses of AGEP’s generalized pustular psoriasis. Ceftriaxone was suspended and a cutaneous biopsy was performed, while introducing prednisone and antihistaminics orally.

The histopathological examination showed evidence of psoriasiform spongiotic dermatitis, with intense dermal edema and migration of neutrophils to the corneal layer. Correlating the findings with the clinical picture, the final diagnosis was AGEP (Figures 3 and 4).

The patient progressed with improved clinical picture and partial regression of the exanthema, as well as total regression of pustules in 5 days. He was discharged and remains under medical follow-up (Figure 5).
In pustular psoriasis, the rash is usually monomorphic, lasts for a longer period of time and is recurrent. It is less flexural than AGEP. Many times it is associated with arthritis and regresses in a period of 10 to 14 days. Histology shows suprabasal hyperkeratosis, papillomatosis and acanthosis. Other important differential diagnoses are: staphylococcal scalded skin syndrome, septicemia by staphylococcus aureus, bacterial folliculitis, subcorneal pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS).\(^5\)

AGEP etiology is strongly associated with macrolides and beta-lactam based agents, but other medications and even viral infections may be related (quinolones, sulfonamides, terbinafine, antimalarials, calcium channel blockers, AINES, spider bites and infections by parvovirus B19, cytomegalovirus, coxsackie B4 and mycoplasma pneumoniae).\(^6\) It is important to remember that the main AGEP-triggering drugs are different from the main drugs implicated in the onset of other severe reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN), resulting mainly from the use of anticonvulsants, although antibiotics are also implicated.

The diagnosis is clinical, histopathologic, and in some cases the contact test, usually performed 4-6 weeks after the clinical picture is resolved, may help. A positive test may confirm the etiology, but a negative test does not exclude it.

The prognosis is good and the disease self-limited, after withdrawal of the triggering drug, unless there is secondary infection of the lesions. A symptomatic treatment is indicated for relief of pruritus and cutaneous inflammation (medium potency topical corticosteroids 2x/day for 1 week), besides antiseptic solutions in the pustular phase to prevent superinfection and emollients in the desquamative phase to reestablish the cutaneous barrier. Only rare severe cases require hospitalization for hydration support and electrolytic equilibrium.

This report stresses the need to include AGEP as possible diagnosis of patient with psoriasis presenting acute pustulosis, although generalized Von Zumbusch’s Pustular Psoriasis is more prevalent in this group of patients.
